Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study

The phosphatidylinositol‐3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2‐negative breast cancer and may play a role in taxane resistance. The phase IB/II TAKTIC trial (NCT01980277) has shown that combining a dual AKT and p70 ribosomal protein S6 kinas...

Full description

Bibliographic Details
Main Authors: Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Nicolas Isambert, Florence Dalenc, Marie Robert, Christelle Levy, Jihane Pakradouni, José Adelaïde, Max Chaffanet, Patrick Sfumato, Emilie Mamessier, François Bertucci, Anthony Goncalves
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Molecular Oncology
Subjects:
AKT
breast cancer
circulating tumor DNA
copy number alterations
low‐coverage whole genome sequencing
survival
Online Access:https://doi.org/10.1002/1878-0261.13188

Internet

https://doi.org/10.1002/1878-0261.13188

Similar Items